Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07374692 · ClinicalTrials.gov registry record · NA
Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors
A NA study of Brain Cancer and Gliomas, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT07374692: Recruiting NA study of Brain Cancer and Gliomas, sponsored by National Cancer Institute (NCI).
NCT07374692 is a NA study of Brain Cancer and Gliomas that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 80 participants, below the 506-participant average among 47 other Brain Cancer trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07374692, a NA study of Brain Cancer and Gliomas, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Primary central nervous system (CNS) tumors grow in the brain and spinal cord. These tumors are rare, but they are difficult to treat and often fatal. SmartMatch is a new technology that tries to help find the best medicines for the particular tumor by testing how small pieces of surgically removed tumor tissue react to different drugs. The study team wants to see if SmartMatch can complete the analysis and generate a report within 21 days from the time of the surgery. Objective: To better understand CNS tumors so doctors can find better ways to treat them in the future. Eligibility: People aged 15 years and older with recurrent CNS tumors. Patient must already be scheduled for a surgery for the tumor at the NIH. Design: The study team will collect a small amount of tumor samples during the planned surgery. They may also use tumor samples from previous procedures. No new or additional procedures will be done for the purpose of this study. The tumor samples will be sent to a lab for SmartMatch analysis. Once completed, the results will be shared with the patient and his/her local doctor. Together they can decide whether to incorporate the results into the treatment plan. It is important to know that the results may or may not be helpful. There will only be one blood test for research. Blood and tissue samples collected may be used for additional analysis. Tumor tissue may be used to grow additional samples for further study. Participants will receive a pathology diagnosis and mutation profile generated by pathologists who specialize in CNS tumors. The study team will seek updates on participant's health approximately every 6 months for 3 years. Tumor samples may also be collected from any additional surgery done at NIH during this time.
Primary Outcome
Point estimates and 95% exact confidence intervals will be calculated using the Clopper-Pearson method
Conditions Studied
Interventions
- OTHER Tumor sample collection
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-02-04 |
| Est. Completion | 2030-12-30 |
| Phase | NA |
What NCT07374692 shows while recruiting
NCT07374692 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 506-participant average among 47 other Brain Cancer trials with a reported enrollment target (84% lower).
The record links to 6 conditions, with Brain Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tumor sample collection is the first listed.
NCT07374692 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT07374692 about?
NCT07374692 is a clinical study titled "Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors". Background: Primary central nervous system (CNS) tumors grow in the brain and spinal cord. These tumors are rare, but they are difficult to treat and often fatal. SmartMatch is a new technology that tries to help find the best medicines for the particular tumor by testing how small pieces of surgic...
What is the current status of trial NCT07374692?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2026-02-04. Estimated completion is 2030-12-30.
What conditions does trial NCT07374692 study?
This clinical trial studies the following conditions: Brain Cancer, Gliomas, Recurrent CNS Tumors, IDH-wildtype Gliomas, IDH-mutant Gliomas.
What interventions are being tested in trial NCT07374692?
The interventions under investigation include: Tumor sample collection (OTHER).
Who is sponsoring clinical trial NCT07374692?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07374692 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07374692's enrollment target sits among peer trials
80 17th of 47 higher than 31 of 47 other Brain Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
RECRUITING · NA
-
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
RECRUITING · NA
-
HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
RECRUITING · NA
-
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
RECRUITING · NA
-
Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
ACTIVE NOT RECRUITING · NA
-
Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI